Treating Acute Leukemias
in Europe

A Worldwide Collaboration to Define and Refine the Most Effective Treatments in Leukemias

Overview

In recent years, progress in the understanding of acute leukemias has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Leukemia Academy to help physicians who treat acute leukemias bridge the gap between innovation and implementation for patient care.

Date and Location

23–24 September 2022, Virtual Meeting

Meeting Content

View the slides and watch the video of Day 1
Virtual Plenary Sessions

View the slides and watch the video of Day 2
Virtual Breakout: Adult ALL Patients

View the slides and watch the video of Day 2
Virtual Breakout: Pediatric ALL Patients

View the slides and watch the video of Day 2
Virtual Breakout: Adult AML Patients

Ask your questions directly to the experts and receive their personal insights on current and novel treatment approaches for pediatric and adult patients with acute leukemias.

Co-chairs

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, USA

Franco Locatelli

Franco Locatelli, MD, PhD

Sapienza, University of Rome
IRCCS Bambino Gesù Children’s Hospital,
Italy

Naval Daver

Naval Daver, MD

MD Anderson Cancer Center, USA

Gail Roboz

Gail J. Roboz, MD

Weill Cornell Medicine and New York-Presbyterian Hospital, USA

Faculty

Josep Ribera

Josep-Maria Ribera, MD, PhD

Catalan Institute of Oncology, University Hospital Germans Trias i Pujol,
Spain

Agnieszka Wierzbowska

Agnieszka Wierzbowska, MD, PhD

Medical University of Lodz,
Poland

Rob Pieters

Rob Pieters, MD, PhD

Princess Máxima Center for Pediatric Oncology, University of Utrecht,
The Netherlands

Nicola Gokbuget

Nicola Gökbuget, MD

University Hospital Frankfurt, Germany

Christina Peters

Christina Peters, MD

St. Anna Children’s Hospital, Austria

Nicolas Boissel

Nicolas Boissel, MD, PhD

Hôpital Saint-Louis, France

Agenda

This 2-day interactive virtual meeting with global experts will focus on the management of acute leukemia patients in Europe

Day 1: Follow presentations, listen to expert opinions on hot topics in leukemias, engage with the faculty in panel discussions on optimal treatment and patient access, and regional challenges across Europe.

Day 2: Join the pediatric, adult, or AML breakout session to learn about treatment strategies for newly diagnosed and relapsed/refractory leukemia patients and attend the patient case-based panel discussions focusing on toxicity management.

Day 1 – PLENARY SESSIONS Friday, 23 September 2022

Chair: Elias Jabbour, MD
Co-chairs: Gail J. Roboz, MD, and Naval Daver, MD

14.30 – 18.00 CEST (UTC +2)

Time (CEST) Topic Presenter
14.30 – 14.40 Welcome and Meeting Overview Elias Jabbour
14.40 – 15.05 What’s New in ALL? Recent Developments in Research and Management TBC
15.05 – 15.25 The Clinical Value of MRD in ALL: How MRD Can Guide the Use of Targeted Agents or Immunotherapy Josep-Maria Ribera
15.25 – 15.45 How to Optimally Sequence CD19-Targeted Approaches in ALL Elias Jabbour
15.45 – 16.10 Hot Topics and Regional Challenges of ALL Management
• Interactive discussion and Q&A
Moderator: Elias Jabbour
All faculty
16.10 – 16.20 Break  
16.20 – 16.45 What’s New in AML? Recent Developments in Research and Management Naval Daver
16.45 – 17.05 Genetic Characterization and Risk Stratification in AML Agnieszka Wierzbowska
17.05 – 17.25 Moving the Treatment of AML to the Outpatient Setting: Is It Feasible? Gail J. Roboz
17.25 – 17.50 Hot Topics and Regional Challenges of AML Management
• Interactive discussion and Q&A
Moderators: Gail J. Roboz and Naval Daver
All faculty
17.50 – 18.00 Session Close Elias Jabbour

Day 2 – BREAKOUT: ADULT ALL PATIENTS Saturday, 24 September 2022

Chair: Elias Jabbour, MD

11.00 – 13.45 CEST (UTC +2)

Time (CEST) Topic Presenter
11.00 – 11.10 Session Open Elias Jabbour
11.10 – 11.35 Optimizing First-Line Therapy in Adult and Older ALL: Integration of Immunotherapy Into Frontline Regimens Nicolas Boissel
11.35 – 12.00 Current Treatment Options for Relapsed ALL in Adult and Older Patients Nicola Gökbuget
12.00 – 12.40 ALL Case-Based Panel Discussion
• Local case 1: Frontline setting (10 min)
• Local case 2: Relapsed/refractory setting (10 min)
• Discussion and Q&A (20 min)
Moderator: Elias Jabbour
Local case presenters
All faculty
12.40 – 12.50 Break  
12.50 – 13.10 Beyond the Horizon: New and Future Treatment Approaches for Adult and Older ALL Nicola Gökbuget
13.10 – 13.35 Interactive Discussion: Treatment Landscape Evolution Moderator: Elias Jabbour
All faculty
13.35 – 13.45 Session Close Elias Jabbour

Day 2 – BREAKOUT: PEDIATRIC ALL PATIENTS Saturday, 24 September 2022

Chair: Franco Locatelli, MD, PhD

10.00 – 12.45 CEST (UTC +2)

Time (CEST) Topic Presenter
10.00 – 10.10 Session Open Franco Locatelli
10.10 – 10.30 How to Use MRD and Genetics for Stratification and Therapy Guidance in First-Line Therapy of Childhood ALL Rob Pieters
10.30 – 10.55 Optimizing First-Line Therapy in Pediatric ALL: How to Balance Cure and Long-term Risks? Rob Pieters
10.55 – 11.35 ALL Case-Based Panel Discussion
• Local case 1: Frontline setting (10 min)
• Local case 2: Management of long-term toxicities (10 min)
• Discussion and Q&A (20 min)
Moderator: Franco Locatelli
Local case presenters
All faculty
11.35 – 11.45 Break  
11.45 – 12.15 Current Treatment Options for Relapsed ALL in Children Christina Peters
12.15 – 12.35 ALL Case-Based Panel Discussion
• Local case 3: Relapsed/refractory setting (10 min)
• Discussion and Q&A (10 min)
Moderator: Franco Locatelli
Local case presenter
All faculty
12.35 – 12.45 Session Close Franco Locatelli

Day 2 – BREAKOUT: AML PATIENTS Saturday, 24 September 2022

Co-chairs: Gail J. Roboz, MD, and Naval Daver, MD

14.30 – 17.15 CEST (UTC +2)

Time (CEST) Topic Presenter
14.30 – 14.40 Session Open Gail J. Roboz and Naval Daver
14.40 – 15.00 Personalized Induction and Maintenance Approaches for AML Gail J. Roboz
15.00 – 15.25 Fit and Unfit AML Patients: How Do We Distinguish? How Do We Treat Differently? Agnieszka Wierzbowska
15.25 – 16.05 AML Case-Based Panel Discussion
• Local case 1: Fit AML (10 min)
• Local case 2: Unfit AML (10 min)
• Discussion and Q&A (20 min)
Moderators: Gail J. Roboz and Naval Daver
Local case presenters
All faculty
16.05 – 16.15 Break  
16.15 – 16.40 Optimizing Management of Relapsed/Refractory AML Naval Daver
16.40 – 17.05 AML Case-Based Panel Discussion
• Local case 3: Relapsed/refractory AML (10 min)
• Discussion and Q&A (15 min)
Moderators: Gail J. Roboz and Naval Daver
Local case presenter
All faculty
17.05 – 17.15 Session Close Gail J. Roboz and Naval Daver